418 related articles for article (PubMed ID: 17191164)
1. Isoniazid's bactericidal activity ceases because of the emergence of resistance, not depletion of Mycobacterium tuberculosis in the log phase of growth.
Gumbo T; Louie A; Liu W; Ambrose PG; Bhavnani SM; Brown D; Drusano GL
J Infect Dis; 2007 Jan; 195(2):194-201. PubMed ID: 17191164
[TBL] [Abstract][Full Text] [Related]
2. Isoniazid bactericidal activity and resistance emergence: integrating pharmacodynamics and pharmacogenomics to predict efficacy in different ethnic populations.
Gumbo T; Louie A; Liu W; Brown D; Ambrose PG; Bhavnani SM; Drusano GL
Antimicrob Agents Chemother; 2007 Jul; 51(7):2329-36. PubMed ID: 17438043
[TBL] [Abstract][Full Text] [Related]
3. Pharmacodynamic evidence that ciprofloxacin failure against tuberculosis is not due to poor microbial kill but to rapid emergence of resistance.
Gumbo T; Louie A; Deziel MR; Drusano GL
Antimicrob Agents Chemother; 2005 Aug; 49(8):3178-81. PubMed ID: 16048921
[TBL] [Abstract][Full Text] [Related]
4. Biphasic kill curve of isoniazid reveals the presence of drug-tolerant, not drug-resistant, Mycobacterium tuberculosis in the guinea pig.
Ahmad Z; Klinkenberg LG; Pinn ML; Fraig MM; Peloquin CA; Bishai WR; Nuermberger EL; Grosset JH; Karakousis PC
J Infect Dis; 2009 Oct; 200(7):1136-43. PubMed ID: 19686043
[TBL] [Abstract][Full Text] [Related]
5. Molecular characterization of isoniazid resistance in Mycobacterium tuberculosis: identification of a novel mutation in inhA.
Leung ET; Ho PL; Yuen KY; Woo WL; Lam TH; Kao RY; Seto WH; Yam WC
Antimicrob Agents Chemother; 2006 Mar; 50(3):1075-8. PubMed ID: 16495272
[TBL] [Abstract][Full Text] [Related]
6. [A simple enzyme test for proving the resistance to isoniazid of Mycobacterium tuberculosis strains].
Homorodean D
Pneumologia; 2005; 54(2):58-61. PubMed ID: 16536002
[TBL] [Abstract][Full Text] [Related]
7. Rapid genotypic assays to identify drug-resistant Mycobacterium tuberculosis in South Africa.
Evans J; Stead MC; Nicol MP; Segal H
J Antimicrob Chemother; 2009 Jan; 63(1):11-6. PubMed ID: 18940875
[TBL] [Abstract][Full Text] [Related]
8. Selection of a moxifloxacin dose that suppresses drug resistance in Mycobacterium tuberculosis, by use of an in vitro pharmacodynamic infection model and mathematical modeling.
Gumbo T; Louie A; Deziel MR; Parsons LM; Salfinger M; Drusano GL
J Infect Dis; 2004 Nov; 190(9):1642-51. PubMed ID: 15478070
[TBL] [Abstract][Full Text] [Related]
9. katG mutations in isoniazid-resistant strains of Mycobacterium tuberculosis isolates from Belarusian patients.
Zaker Bostanabad S; Titov LP; Slizen VV; Taghikhani M; Bahrmand A
Tuberk Toraks; 2007; 55(3):231-7. PubMed ID: 17978919
[TBL] [Abstract][Full Text] [Related]
10. Molecular characterisation of isoniazid-resistant Mycobacterium tuberculosis isolated from new cases in Lagunes region (Côte d'Ivoire).
N'Guessan KR; Dosso M; Ekaza E; Kouakou J; Jarlier V
Int J Antimicrob Agents; 2008 May; 31(5):498-500. PubMed ID: 18313272
[No Abstract] [Full Text] [Related]
11. [KatG Ser3 15Thr mutation as the main reason of isoniazid resistance in Mycobacterium tuberculosis isolated in the Novosibirsk and Kemerovo Regions].
Voronina EN; Vikhrova MA; Khrapov EA; Kinsht VN; Norkina OV; Gorbunova EV; Shabaldin AV; Glushkov AN; Krasnov VA; Filipenko ML
Mol Gen Mikrobiol Virusol; 2004; (3):8-11. PubMed ID: 15354935
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the bactericidal activity of various fluoroquinolones against Mycobacterium tuberculosis in an in vitro experimental model.
Cremades R; Rodríguez JC; García-Pachón E; Galiana A; Ruiz-García M; López P; Royo G
J Antimicrob Chemother; 2011 Oct; 66(10):2281-3. PubMed ID: 21733966
[TBL] [Abstract][Full Text] [Related]
13. Public health impact of isoniazid-resistant Mycobacterium tuberculosis strains with a mutation at amino-acid position 315 of katG: a decade of experience in The Netherlands.
van Doorn HR; de Haas PE; Kremer K; Vandenbroucke-Grauls CM; Borgdorff MW; van Soolingen D
Clin Microbiol Infect; 2006 Aug; 12(8):769-75. PubMed ID: 16842572
[TBL] [Abstract][Full Text] [Related]
14. Lack of correlation between embB mutation and ethambutol MIC in Mycobacterium tuberculosis clinical isolates from China.
Shi R; Zhang J; Otomo K; Zhang G; Sugawara I
Antimicrob Agents Chemother; 2007 Dec; 51(12):4515-7. PubMed ID: 17846128
[TBL] [Abstract][Full Text] [Related]
15. Understanding the action of INH on a highly INH-resistant Mycobacterium tuberculosis strain using Genechips.
Fu LM; Shinnick TM
Tuberculosis (Edinb); 2007 Jan; 87(1):63-70. PubMed ID: 16890025
[TBL] [Abstract][Full Text] [Related]
16. Frequency of embB codon 306 mutations in ethambutol-susceptible and -resistant clinical Mycobacterium tuberculosis isolates in Kuwait.
Ahmad S; Jaber AA; Mokaddas E
Tuberculosis (Edinb); 2007 Mar; 87(2):123-9. PubMed ID: 17289435
[TBL] [Abstract][Full Text] [Related]
17. Transfer of a point mutation in Mycobacterium tuberculosis inhA resolves the target of isoniazid.
Vilchèze C; Wang F; Arai M; Hazbón MH; Colangeli R; Kremer L; Weisbrod TR; Alland D; Sacchettini JC; Jacobs WR
Nat Med; 2006 Sep; 12(9):1027-9. PubMed ID: 16906155
[TBL] [Abstract][Full Text] [Related]
18. [Comparison of the proteomes of isoniazid-resistant Mycobacterium tuberculosis strains and isoniazid-susceptible strains].
Jiang X; Gao F; Zhang WH; Hu ZY; Wang HH
Zhonghua Jie He He Hu Xi Za Zhi; 2007 Jun; 30(6):427-31. PubMed ID: 17673015
[TBL] [Abstract][Full Text] [Related]
19. The extreme sensitivity of Mycobacterium tuberculosis to the front-line antituberculosis drug isoniazid.
Deretic V; Pagán-Ramos E; Zhang Y; Dhandayuthapani S; Via LE
Nat Biotechnol; 1996 Nov; 14(11):1557-61. PubMed ID: 9634820
[TBL] [Abstract][Full Text] [Related]
20. Analysis of the role of Mycobacterium tuberculosis kasA gene mutations in isoniazid resistance.
Sun YJ; Lee AS; Wong SY; Paton NI
Clin Microbiol Infect; 2007 Aug; 13(8):833-5. PubMed ID: 17501974
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
